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Abstract
Background: A Task Force from the International Society of Pharmacoeconomics and Outcomes Research (ISPOR)
provides recommendations on how to systematically identify and appraise health state utility (HSU) weights for
cost-effectiveness analyses. We applied these recommendations to conduct a systematic review (SR) to identify HSU
weights for different stages of chronic kidney disease (CKD), renal replacement therapy (RRT) and complications.
Methods: MEDLINE® and Embase were searched for interventional and non-interventional studies reporting HSU
weights for patients with CKD stages 1–5 or RRT. As per ISPOR Task Force Guidance, study quality criteria,
applicability for Health Technology Assessment (HTA) and generalisability to a broad CKD population were used to
grade studies as either 1 (recommended), 2 (to be considered if there are no data from grade 1 studies) or 3 (not
recommended).
Results: A total of 17 grade 1 studies were included in this SR with 51 to 1767 participants, conducted in the UK,
USA, Canada, China, Spain, and multiple-countries. Health related quality of life (HRQL) instruments used in the
studies included were EQ-5D-3L (10 studies), SF-6D (4 studies), HUI2/HUI3 (1 study), and combinations (2 studies).
Although absolute values for HSU weights varied among instruments, HSU weights decreased with CKD severity in
a consistent manner across all instruments.
Conclusions: This SR identified HSU weights for a range of CKD states and showed that HRQL decreases with CKD
progression. Data were available to inform cost-effectiveness analysis in CKD in a number of geographies using
instruments acceptable by HTA agencies.
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Background
Chronic kidney disease (CKD) has a substantial impact
on patients’ health and life expectancy. CKD has been
estimated to affect between 10 and 15% of the popula-
tion in the U.S. and Canada [1, 2]. CKD can be a pro-
gressive disease and the leading causes include diabetes
(38%), high blood pressure (26%), and glomeruloneph-
ritis (16%) [3]. Progression to end-stage renal disease
(ESRD) leaves the patients reliant on dialysis or a kidney
transplant [4]. CKD also leads to substantial healthcare
resource use. The total Medicare spending on both CKD
and ESRD was over $114 billion in 2016 [5].
The KDIGO (Kidney Disease: Improving Global
Outcomes) 2012 guidelines recommended that CKD
patients should be categorised based on cause, glomeru-
lar filtration rate (GFR) category, and albuminuria
category in order to aid in predicting CKD prognosis.
Despite guideline directed management of risk factors
and use of renin angiotensin aldosterone system inhibi-
tors (RAASi), disease progression, adverse clinical out-
comes and mortality rates remain high in patients with
CKD, particularly in those patients at risk such as those
with moderately or severely increased albuminuria,
highlighting a clinical need for new treatments to delay
renal disease progression and improve health related
quality of life (HRQL).
Since the introduction of health technology assessment
(HTA) agencies across the world, the decision to adopt
new treatments is becoming more frequently based on
the results of cost-effectiveness analyses. The cost-
effectiveness of new treatments is influenced by HRQL
weights (referred to as health state utility [HSU]
weights). HSU weights range between 0 and 1, with 1
representing the valuation of perfect health and 0 repre-
senting the valuation of death and are used to estimate
quality adjusted life years (QALYs). A systematic review
(SR) reported that most cost-effectiveness models in
CKD utilised a framework based on disease progression
defined by a worsening in GFR stage or albuminuria
category [6].
A Task Force from the International Society of
Pharmacoeconomics and Outcomes Research (ISPOR)
led by Brazier and colleagues (2019) provided recom-
mendations on how to systematically identify and ap-
praise HSU weights for cost-effectiveness analysis. The
recommendations were divided into four sections which
describe: (1) iterative search strategy; (2) review process
to include studies based on inclusion criteria and data
quality; (3) data to be extracted from each study; (4)
basis for selecting HSUs to inform a cost-effectiveness
analysis (e.g. data availability for a country of interest or
data availability using a specific instrument) (Fig. 1).
The impact of dialysis and renal transplantation on
HSU weights has been reported in previous SRs,
however, it remains uncertain how the magnitude of
HSU weights change as CKD progresses between stages
1 and 5 [7–11].
The aim of this SR was to identify HSU weights to in-
form cost-effectiveness modelling in CKD applying
current best practices, and the review was conducted to
provide an international perspective.
Methods
Search strategy
This SR was based on a prespecified protocol and
conducted in accordance with the standards prescribed
by the ISPOR Task Force (but also reflects best practice
at the Centre for Reviews and Dissemination, National
Institute for Health and Care Excellence (NICE), and the
Cochrane Collaboration) [12–15]. The search was con-
ducted in both MEDLINE (PubMed) and Embase
(OVID) in August 2019. The full search strategy is
provided in Additional file 1. Grey literature searches in-
cluded conference proceedings of three major nephrol-
ogy congresses and one health economics congress held
between 2017 and 2019, and reports from four major
HTA agencies (Additional file 2). The bibliographies of
relevant published SRs and cost-effectiveness analyses
were hand-searched to find additional articles that were
not identified in the electronic database searches.
Two independent reviewers (JC, JGS) screened the title
and abstract of each record (stage 1), as well as the full
texts of all potentially eligible records identified in stage
1 (stage 2). A third independent reviewer (AL) resolved
any disagreements.
Study inclusion criteria are shown in Table 1 and are
based on the PICOS (population, intervention, compara-
tor, outcome, study) framework.
Critical appraisal
Each study was assessed against the following criteria:
 The study was conducted in a CKD population
 The study reports original empirical HSU weights
 Data were collected using a generic HRQL measure
(i.e. EQ-5D, short-form 6-dimention [SF-6D] or a
mappable equivalent such as short-form 36 [SF-36]
or short-form 12 [SF-12]; or the Health Utility Index
[HUI])
 The study sample size was at least 25 patients
 The study was conducted in a country of interest
(i.e., USA, Canada, Australia, China, UK, Spain,
Italy, France or Germany)
 HSU weights were presented in a comprehensive
way that is useful to inform cost-effectiveness
analysis (e.g. HSU weights were available by CKD
stage)
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Table 1 Criteria for including studies in the review
i. Population People with any stage CKD including patients on dialysis (haemodialysis or peritoneal dialysis) or with a renal transplant;
any gender, any location, and any severity of CKD. Populations must be representative of the CKD population (i.e., general
comorbidities, reasonable age range) and be greater than 25 people in size. Subgroups of interest include (not limited to):
CKD patients with albuminuria (normo-, micro-, macro-albuminuria), T2DM, glomerulonephritis, IgA nephropathy.
ii. Interventions/comparators All interventions and comparative data were included. Where the intervention is not relevant for the study purposes in
some cases only baseline or placebo arm data is included.
iii. Outcomes Health state utilities from standardised generic multi-attribute utility measures such as EQ-5D, SF-6D or Health Utilities
Index (HUI).
HSUs for all CKD stages, dialysis modalities (haemodialysis and peritoneal dialysis), or renal transplant.
Disutility associated with cardiovascular events commonly included in health economic models in CKD (acute and chronic
where available): myocardial infarction, stroke, heart failure.
Disutility associated with adverse events commonly included in health economic models in CKD: potassium imbalances
(hypo- and hyperkalaemia), volume depletion, acute kidney injury, major hypoglycaemic events, diabetic ketoacidosis,
fractures, amputations (minor/major or toe, foot, limb, etc.).
Impact of comorbidities or patient characteristics on HSUs: albuminuria (normo-, micro-, macro-albuminuria), T2DM,
hypertension, heart failure or cardiovascular disease, age or sex on HSUs.
Impact of complications related to renal replacement therapies on HSUs: dialysis related complications (e.g. vascular access
thrombosis), renal transplant failure, renal transplant surgery.
iv. Study Designs Interventional or non-interventional research.
v. Other requirements Records from January 1, 1999 to present (August, 2019) only.
Abstract and full-text must be available in English text.
Abbreviations: CKD chronic kidney disease, EU5 France, Germany, Italy, Spain, UK, HSU health state utility, HUI health utility index, IgA immunoglobulin A SF-6D,
Short Form questionnaire-6 Dimensions, T2DM type 2 diabetes
Fig. 1 Brazier (2019) HSU identification and selection process. Abbreviations: HSU, health state utility
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To weigh both data quality and data appropriateness
as recommended by Brazier and colleagues (2019), each
study that met the critical appraisal at stage 1 was then
reviewed in full in stage 2 and graded from 1 to 3 with
consideration to the presence of bias, alignment with
HTA criteria, and general compliance with our initial se-
lection criteria (Table 2). To assess bias, each study’s
methodology was examined for selection bias, bias in
data analysis or interpretation, drop out or missing data,
or bias in study execution such as unblinding in rando-
mised control trials.
Grade 1 studies were considered most appropriate for
HTA. If data for a specific health state was not available
using Grade 1 studies, then, Grade 2 studies would be
reviewed to identify a missing value following the
iterative approach recommended by Brazier and col-
leagues (2019). Grade 3 studies were considered to be
inappropriate.
Relevant data, as recommended by Brazier and
colleagues (2019), was extracted from the included
studies into a prespecified extraction grid.
Results
Electronic database searches identified 1091 records.
After title/abstract screening, 150 studies were selected
for full-text review, of which 52 met the final inclusion
criteria. The grey literature identified 83 studies,
although no new studies met our inclusion criteria
(Additional file 2). The article selection process is
displayed in Fig. 2.
Of the 52 included studies, the grading process identi-
fied 17 Grade 1, 30 Grade 2, and 5 Grade 3 studies
(Additional file 3). Data were extracted for the Grade 1
studies (Additional file 4). Fourteen of the studies re-
ported more than one CKD HSU weight, resulting in a
total of 58 CKD HRQL estimates across different health
states (i.e., CKD stages, haemodialysis (HD), peritoneal
dialysis (PD) and renal transplant (Trx)).
Ten studies (59%) used the EQ-5D-3L, four (24%) used
the SF-6D, one (6%) used the HUI3, and two (12%) used
multiple instruments (HUI2 and HUI3; EQ-5D-3L and
HUI3). Of the reported HSU weights, 18 (41%) described
dialysis patients, 17 (39%) described transplant patients,
and 9 (21%) described cohorts by CKD stages. Studies
were reported from Canada (n = 4; 29%), the UK (n = 3;
18%), the US (n = 3; 28%), Spain (n = 2; 12%), and China
(n = 2; 12%), and two studies (12%) were multinational.
A summary of key study characteristics is reported in
Table 3.
HSU weights for the different CKD health states are
reported in Table 4. HRQLs for haemodialysis and post-
transplant patients were the most common. There is a
scarcity of data describing HRQL for patients in CKD
stages 1–5; only one study was identified that reported
an HSU value for stage 2 patients and no studies re-
ported HSUs for stage 1 patients.
Four longitudinal studies reported HSU weights.
Limited data were available describing HRQL changes
with disease progression. Regarding HRQL in patients
undergoing RRT, HSU weights increased with time
(Table 5).
Mean weighted HSU weights for the different CKD
health states according to instrument are reported in
Fig. 3. There is clear variation in utility values across
instruments. However, there is an overall consistent
trend with each instrument showing a reduction in
HRQL with CKD progression. HRQL is lowest with
dialysis. HSU weights reported using SF-6D indicate no
difference between haemodialysis and peritoneal dialysis
while HSU weights are lower for peritoneal dialysis when
using EQ-5D-3L. HRQL increases after renal
transplantation.
Only one study identified in our SR reported the im-
pact of adverse events or complications on CKD patients
on dialysis [18]. The HSU weights reported are shown in
Table 6. No studies reported the impact of adverse
events or complications on patients with CKD stage 1–5
or after a renal transplant.
Study quality is reported in Additional file 5. Since all
analysed studies met our grade 1 screening require-
ments, overall study quality was high. Quality assess-
ment reported a lack of clarity in 7 studies regarding
drop out or missing data rates. Lee et al. reported a low
33% response rate but was retained due to the question-
naire administration method (survey packets were
mailed to patients’ houses) [19].
Discussion
This SR was designed to identify HSU weights for a
range of CKD health states using methods promoted by
Brazier and colleagues (2019) and other best guidance
available. To our understanding, this is the first SR to re-
port HSU weights for CKD stages 2–5, as well as RRT,
as previous SRs focused on RRT only [7, 10, 33–37].
The review identified a large number of published
studies that reported HSU weights for CKD populations.
By focusing to the most generalisable and reliable Grade
1 studies, we hope to present the most accurate sum-
mary of HSU weights in CKD.
This is also the first SR to have been undertaken in
the area of HSU weights since the Brazier and
colleagues (2019) guidance on SR methods for the
identification of HSU weights for cost-effectiveness
analysis was released [12]. Based on our experience of
implementing the guidance, we found that the recom-
mended approach worked well and the guidance
provided a very good rationale and set of methods for
identifying the most relevant data.
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According to the ISPOR Task Force on Indirect Treat-
ment Comparisons Good Research Practices, conducting
a meta-analysis on this topic may have been appropriate.
However, the Brazier and colleagues (2019) guidance for
identification of HSU weights in particular does not spe-
cify the need for this type of analysis. We believe this SR
more directly addresses the needs of decision-making
entities in different countries, as ideal data for decision-
making would be country-specific with a relevant
presence of comorbidities, settings, HSU instruments,
and date-of-publication ranges - entities that may be lost
in meta-analysis.
The review found an overall trend across studies for a
decline in HSU scores as CKD deteriorated, (based on
GFR). This fits with clinical expectation, but it is a point
worth making because we believe that it provides some
justification or validation of the identified HSU weights.
Different factors may affect HRQL decline at different
CKD stages. For instance, reductions in HRQL in early
CKD stages may be driven by the presence of comorbid-
ities such as diabetes, while a decline in HRQL in more
advanced CKD stages may also be driven by an increase
in the incidence of heart failure, and cardiovascular
complications such as myocardial infarction or stroke
Table 2 Record Grading Scale
1 Study meets all HTA selection criteria and has no apparent sources of significant bias
2 Study meets HTA selection criteria but may be subject to bias (e.g. may need the application of a mapping algorithm to derive HSU weights or
there may be study methodology bias)
3 Study does not meet HTA selection criteria (e.g. not a population representative of the CKD population)
Abbreviations: CKD chronic kidney disease, HTA health technology assessment, HSU health state utility
Fig. 2 PRISMA Diagram. Abbreviations: CKD, chronic kidney disease; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses
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which could also have a substantial impact on HRQL
[38–41]. However, it is difficult to determine the cause
of any decline in HRQL when exploring published data
because we are limited to the data that have been in-
cluded in the publication. This is one important limita-
tion of the published data and of this SR. The studies
included varied in terms of their design (cross-sectional
survey, randomised trial, prospective observational
study) and used different instruments which made com-
parisons between them challenging. Although a similar
declining trend was observed with CKD progression
across instruments, absolute HSU values were different
Table 3 Main study characteristics
Author (Year) N
Mean age (SD)









Stage 3 CKD only.






Moderate to severe secondary
hyperparathyroidism on HD.




10 dialysis/ renal insufficiency units.
Alberta, Canada.
CKD stage 4 and 5 expected to
start dialysis within 12 months.
Patients currently receiving HD or
PD (started in last 12 months).




10 dialysis/ renal insufficiency units.
Alberta, Canada.
CKD stage 4 and 5 expected to start
dialysis within 12 months.
Patients currently receiving HD or







Patients from a single nephrology and
dialysis site.
USA.
Two groups defined by:
-GFR between 30 and 70 ml/min.
-GFR < 30 ml/min.




40 home and hospital dialysis centres.
Australia, China, Canada, and New
Zealand.
Adult patients requiring maintenance
HD.
Jesky (2016) 745 patients.





Pre-dialysis CKD and GFR < 30 ml/min.
Lee (2005) 416 patients.
Males: 58.2 years.
Females: 55.5 years.
58.9% Cross-sectional study. Renal unit departmental database.
South Wales, UK.
Patients receiving HD, waiting to start
HD or after receiving a renal transplant.
Manns (2002) 128 patients.
61.8, 95%CI (59.1, 64.6) years.
56.3% Cross-sectional study. Southern Alberta Renal Program.
Alberta, Canada.
All participants had received over
6 months of HD.
Manns (2003) 192 patients.
60.8, 95%CI (58.6, 63.0) years.
55.7% Cross-sectional study. Southern Alberta Renal Program.
Alberta, Canada.
All participants had received over
6 months of HD.




Southern Alberta Renal Program.
Alberta, Canada.
In- or home conventional HD
3 times weekly.
Neri (2011) 386 patients.
GFR > 90 ml/min = 48.1 (16.2)
years.
GFR 90–60 ml/min = 52.2
(13.4) years.
GFR 59–30 ml/min = 51.5
(11.8) years.
GFR 29–15 ml/min = 52.2
(12.1) years.
GFR < 15 ml/min = 43.2 (14.6)
years.
61.4% Cross-sectional study. Two outpatient clinics.
Midwest, USA.
Kidney transplant patients.






Adult patients with end-stage renal
disease who received a kidney transplant.






Pre-renal transplant and 12 months
post-renal transplant.
Ortega (2013) 206 patients.
53.4 (12.9) years.
61.2% Cross-sectional study. 39 transplantation units.
Spain.
Renal transplant patients 6–24 months
post-renal transplant.
Pan (2018) 315 patients.
57.3 (14.9) years.




Wong (2019)a 399 patients.
57.3 (12.7) years.
61.9% Cross-sectional study. Hospital, community HD centres or
home HD or PD.
Hong Kong.
Patients undergoing home based
nocturnal HD, PD, hospital or
community HD.
Abbreviations: CKD chronic kidney disease, GFR glomerular filtration rate, HD haemodialysis, PD peritoneal dialysis, SD standard deviation
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across instruments with EQ-5D-3L reporting the highest
values. This could reflect that sensitivity to capture the
impact of CKD progression on HRQL may be different
between the instruments reported in this systematic
review. This could also present a challenge when esti-
mating QALYs gained in cost-effectiveness analyses of
new treatments for CKD. As a consequence, incremental
cost-effectiveness ratios could be different depending on
Table 4 HSU weights by subgroup
Utility Value
(SD)
Sample Size (N) Instrument Country Source
CKD Stage 2
0.85 (95% CI: 0.70–1) 29 EQ-5D-3L UK [16]
CKD Stage 3
Stage 3a 0.80 (95% CI: 0.69–1) 45 EQ-5D-3L UK [16]
Stage 3b 0.80 (95% CI: 0.68–1) 173 EQ-5D-3L UK [16]
Stage 3 0.67 (0.31) 50 HUI3 USA [17]
CKD Stage 4 0.74 (95% CI: 0.62–0.85) 423 EQ-5D-3L USA [16]
0.55 (0.34) 65 HUI3 USA [17]
CKD Stage 5 0.54 (0.36) 28 HUI3 USA [17]
0.73 (95% CI: 0.62–1) 75 EQ-5D-3L UK [16]
Haemodialysis 0.75 (0.25) 1767 EQ-5D-3L Various [18]
0.44 (0.32) 99 EQ-5D-3L UK [19]
0.78 (0.24) 200 EQ-5D-3L Various [20]
0.60 (95% CI: 0.55, 0.64) 128 EQ-5D-3L Canada [21]
0.69 (95% CI: 0.63,0.76) 51 EQ-5D-3L Canada [22]
0.54 (0.31) 271 HUI3 USA [17]
0.75 (0.11) 315 SF-6D China [23]
0.73 (0.11) 135 SF-6D China [24]
0.78 (0.09) 41 SF-6D China [24]
0.79 (0.11) 118 SF-6D China [24]
Peritoneal Dialysis 0.53 (0.34) 64 EQ-5D-3L UK [19]
0.78 (0.11) 103 SF-6D China [24]
Unspecified Dialysis 0.54 (0.31) 38 HUI3 USA [17]
0.74 (0.20) 185 HUI2 Canada [25]
0.58 (0.26) 185 HUI3 Canada [25]
0.67 (0.13) 185 SF-6D Canada [26]
Pre-Transplant NR
Post-Transplant
CKD stage 1–2 0.79 (0.25) 386 HUI3 USA [27]
CKD stage 3 0.87 (0.14) 172 EQ-5D-3L USA [27]
CKD stage 3 0.75 (0.26) 172 HUI3 USA [27]
CKD stage 4 0.87 (0.10) 51 EQ-5D-3L USA [27]
CKD stage 4 0.74 (0.22) 51 HUI3 USA [27]
CKD stage 5 0.82 (0.12) 19 EQ-5D-3L USA [27]
CKD stage 5 0.67 (0.33) 19 HUI3 USA [27]
CKD stage not reported 0.71 (0.27) 209 EQ-5D-3L UK [19]
CKD stage not reported 0.77 (NR) 126 SF-6D Spain [28]
CKD stage not reported 0.76 (NR) 80 SF-6D Spain [28]
Abbreviations: CKD chronic kidney disease, HUI2 Health Utilities Index Mark 2, HUI3 Health Utilities Index Mark 3, NR not reported, RRT renal replacement therapy,
SD standard deviation, SF-6D Short Form questionnaire-6 Dimensions
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the instrument used and, potentially, this could result in
different recommendations for the adoption of new
treatments for CKD by HTA agencies. Variability in
HSU weights between instruments remains a source of
bias when combining results from studies using different
instruments. This could be avoided by only including
studies which use one specific instrument. While the
number of patients assessed differed substantially be-
tween studies, by HSU instruments used and CKD
stages, this did not seem to influence HSUs reported as
they seemed aligned for each instrument and CKD stage
regardless of sample size. While HSU weights were low-
est for dialysis, it was not clear if HSU differs between
haemodialysis and peritoneal dialysis as different trends
Table 5 HSU weights reported in longitudinal studies
Baseline 3Months 6 Months 12months Country Instrument Source
CKD stage 2 NR
CKD stage 3 0.67 (0.30) 0.67 (0.29) UK EQ-5D-3L [29]
CKD stage 3a NR
CKD stage 3b NR
CKD stage 4 NR
CKD stage 5 NR
Haemodialysis 0.65 (0.027) 0.62 (0.030) Canada EQ-5D-3L [30]
Peritoneal dialysis 0.64 (0.063) 0.67 (0.046) Canada EQ-5D-3L [30]
Transplant Pre-Transplant Post-Transplant
0.74 (0.21) 0.81 (0.19) 1.0 (0) 0.82 (0.20) Spain EQ-5D-3L [31]
0.61 (NR) 0.74 (NR) USA EQ-5D-3L [32]
0.78 (NR) 0.86 (NR) USA EQ-5D-3L [32]
Abbreviations: CKD chronic kidney disease, HSU health state utility, NR not reported
Fig. 3 Mean HSU weights by state presented by instrument. HSU values are weighted averages calculated using subgroup population sizes; Error
bars represent standard error. Abbreviations: CKD, chronic kidney disease; HSU, health state utility; HUI2, Health Utilities Index Mark 2; HUI3, Health
Utilities Index Mark 3; SF-6D, Short Form questionnaire-6 Dimensions
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were noted between the instruments used. Further
research should be conducted to increased the under-
standing of these differences.
A number of aspects may affect the mix of patients in-
cluded in the studies reported in this SR and, therefore,
the eventual HSU weights reported. For example, pa-
tients receiving in-centre dialysis may have more comor-
bidities and complications than patients that are good
candidates for peritoneal dialysis, dialysis at home or
nocturnal dialysis. Patients with less severe kidney dis-
ease or higher HRQL may also be more likely to respond
to voluntary questionnaires or participate in trials, po-
tentially skewing the data. Further, it is possible that
geographical variations may arise due to differences in
clinical practice but also how people interpret HRQL
questionnaires.
Regression methods such as those applied by Briggs
and colleagues (2012) provide a way to estimate HSUs
from longitudinal studies for different CKD stages
improving the precision of the effects and understand
their origin. Regression analyses of large datasets allow
us to understand the impact of CKD related events on
HRQL as well as understanding the influence of covari-
ates and so this offers advantages over SR methods. It
may also be possible to explore some of these issues with
meta-regression type techniques. However, the studies
are not consistent in the information that they present
which makes it difficult to compare these variables
systematically. Alternatively, it could be assumed that a
‘true’ score for a specific health state lies within the
range of scores that have been identified from the review
for a specific health state. Therefore, cost-effectiveness
analysis could be informed by the range of scores as
opposed to a single point estimate.
All studies used generic instruments of health rather
than disease-specific instruments, but despite this the
HSU weight varied substantially between different in-
struments (Fig. 3). This figure showed that the HUI3
questionnaire produces lower HRQL scores in compari-
son to the SF-6D and EQ-5D-3L. Higher HSU weights
were reported with the SF-6D. SF-6D values for dialysis
patients in particular, (0.76, and 0.78 for haemodialysis
and peritoneal dialysis, respectively) seemed high consid-
ering that these applied to patients receiving dialysis. If
the measures are not in agreement, then this could be
explored (and perhaps controlled for) using a meta-
regression approach. Where possible, HSU weights used
in a cost-effectiveness analysis could be limited to a
single instrument relevant to the specific research
question for a cost-effectiveness analysis such as the EQ-
5D-3L for cost-effectiveness analyses submitted to NICE
in England.
In 2012, KDIGO provided guidelines for the categor-
isation of patients according to GFR and albuminuria
[42]. Our SR did not find any studies that reported HSU
weights based on both GFR and albuminuria or
albuminuria alone. A data gap exists to understand the
impact of albuminuria on HRQL. Additional data gaps
exist around the reporting of HSUs related to CKD stage
1, adverse events and complications in patients with
CKD.
Conclusions
To our knowledge, this is the first SR examining HSU
scores for patients with CKD stages 1–5 with stratifica-
tion by CKD stage. This is also one of the first reviews
to apply the Brazier and colleagues (2019) guidance.
There were sufficient data to provide weighted mean
HSU weights for most CKD stages of interest [2–5] and
RRT. No data was found reporting HSUs weights
according to the KDIGO 2012 GFR/albuminuria
categories. The findings from the SR illustrate how
HRQL is worse for patients with worse renal function.
Although similar trends were seen, notable differences
in absolute values were identified across instruments
highlighting potential differences in sensitivity to cap-
ture changes in HRQL in patients with CKD. This
could result in the estimation of different QALYs
gained in cost-effectiveness models and could affect the
recommendation to adopt new treatments for CKD by
HTA agencies. Regression methods are an option to
provide refined HSU values from longitudinal studies
while meta-analytical methods could help explore dif-
ferences when using aggregate data.
Table 6 HSU weights related to complications in patients on haemodialysis [18]





Myocardial Infarction 0.52 (0.47–0.58) 0.66 (0.57–0.76)
Hospitalisation for unstable angina 0.54 (0.46–0.63) 0.60 (0.49–0.71)
Stroke 0.50 (0.41–0.60) 0.49 (0.30–0.68)
Heart Failure 0.58 (0.54–0.63) 0.66 (0.59–0.73)
Bone Fracture 0.35 (0.30–0.40) 0.58 (0.51–0.65)
Abbreviations: CKD chronic kidney disease, HSU health state utility
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